Corbus Pharmaceuticals Holdings (CRBP) Receivables - Net (2019 - 2021)

Corbus Pharmaceuticals Holdings has reported Receivables - Net for 3 years, with the latest figure at $2.5 million in Q3 2021.

• On a quarterly basis, Receivables - Net rose 160.39% year-over-year to $2.5 million in Q3 2021; TTM through Sep 2021 was $2.5 million, a 160.39% increase from a year earlier, with the FY2020 full-year figure at $1.6 million, down 39.64% from the prior year.
• Receivables - Net was $2.5 million for Q3 2021 at Corbus Pharmaceuticals Holdings, roughly flat from $2.5 million in the prior quarter.
• The five-year high for Receivables - Net was $4.4 million in Q1 2020, with the low at $960091.0 in Q3 2020.
• Average Receivables - Net over 3 years is $2.5 million, with a median of $2.5 million recorded in 2021.
• The largest YoY upside for Receivables - Net was 160.39% in 2021 against a maximum downside of 43.73% in 2021.
• Over 3 years, Receivables - Net stood at $2.7 million in 2019, then sank by 39.64% to $1.6 million in 2020, then soared by 54.48% to $2.5 million in 2021.
• The last three Receivables - Net figures came in at $2.5 million (Q3 2021), $2.5 million (Q2 2021), and $2.5 million (Q1 2021), per Business Quant data.